Editorial pubs.acs.org/chemneuro
2015: A New Impact Factor for ACS Chemical Neuroscience and New Topline Data for Global Pharmaceutical Products
T
Table 1. Top 20 Global Prescription Drugs in 2015 in Terms of Sales3
he 2015 Thompson Reuters Journal Citation Reports was just released, and ACS Chemical Neuroscience held its position. Our 2015 Impact Factor (IF) was 4.348, comparable in 2014 (IF = 4.362), while our 5 year IF increased to 4.51.1,2 In 2015, we reached a new high in terms of both citations (2574, an ∼37% increase over 2014) and published manuscripts (191, an ∼48% increase). So far this year, we are beating 2015 in terms of citations. So, relative to our peer Journals, how are we doing? Once again, ACS Chemical Neuroscience is above Molecular Pharmacology (IF = 3.93), Journal of Pharmacology & Experimental Therapeutics (IF = 3.76), Journal of Neurochemistry (IF = 3.82), and Psychopharmacology (IF = 3.54). ACS Chemical Neuroscience is also indexed in the Medicinal Chemistry category, and is right behind the Journal of Medicinal Chemistry (IF = 5.52), and outperforming ChemMedChem (IF = 2.98), European Journal of Medicinal Chemistry (3.90), Medicinal Chemistry Communications (2.31), and ACS Medicinal Chemistry Letters (IF = 3.35).1 We at ACS Chemical Neuroscience are very happy to provide a Journal that encompasses both classical neuroscience and neuropharmacology as well as neurosciencebased medicinal chemistry. Thanks to all of our authors and reviewers that helped sustain ACS Chemical Neuroscience as a leading Journal in the field, and to our dedicated team of Associate Editors (Anne Andrews, Jacob Hooker, and Kathryn Cunningham) and key ACS staff (Jitesh Soares). While we were hoping for a boost in impact factor in 2015, ACS Chemical Neuroscience held steady while many other Journals slipped in the 2015 IF rankings. 2016 is looking great, and we greatly value your continued submissions (Articles, Reviews, Viewpoints). 2015 was also a strong year for the global pharmaceutical industry, as IMS Institute for Healthcare Informatics3,4 just released data showing a 9.5% growth in sales ($954.1 billion in 2015, up from 943.9 billion in 2014). The top 20 prescription drugs in terms of global sales (Table 1) are notably different from 2014, yet still represent a fairly equal split between small molecules and biologics.3,4 Patent expirations and new antiviral product launches have completely reshaped the global market share of pharmaceuticals. The antipsychotic Abilify witnessed an impressive 19.2% increase in sales in 2014 (from $7.8 billion in 2013 to $9.2 billion in 2014); however, patent expiration resulted in a significant 36.3% loss in global sales ($5.799 billion). The HCV market once again dominated in 2015, with Gilead paving the way. In 2014, the HCV curative agent, Sovaldi, generated an unprecedented 19 262% growth, increasing sales from $70 million in 2013 to $9.3 billion in 2014!3,4 However, in 2015, global sales decreased 28.2% (6.578 billion) due to Gilead’s new product Harvoni (a combination of ledipasvir and sofosbuvir), which placed #1 in terms of global sales ($18.144 billion, an 1159% growth over 2014 sales of $1.565 billion). Biologics such as Humira and Lantus also increased sales in 2015 to $14.950 billion (27.7% increase) and $11.458 billion (14.6% increase), respectively. Other major gainers were Novorapid and Xarelto, while Nexium slid. © 2016 American Chemical Society
rank
product
sales (US $BN)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Harvoni Humira Lantus Enbrel Crestor Remicade Seretide Sovaldi MabThera Avastin Lyrica Abilify Novorapid Herceptin Januvia Spiriva Xarelto Nexium Copaxone Neulasta
18.1 14.9 11.4 9.4 8.6 8.1 7.9 6.5 6.2 6.1 6.0 5.8 5.6 5.5 5.4 5.3 5.1 5.0 5.0 4.7
Overall, the world population enabled “blockbuster” (sales > $1 billion) status for over 40 drugs in 2015.3 The top 20 global therapy areas were little changed relative to 2014 (Table 2), and once again, the top therapy areas once again did not correlate with the top prescription drugs in terms of sales.3,4 In 2015, the top five therapy areas were oncology ($78.9 billion, a 14% increase), antidiabetes ($71.4 billion, a 19% increase), pain ($59.7 billion, a 2.5% increase), autoimmune diseases ($41.9 billion, a 19.7% increase), and antihypertensives ($41.3 billion, a net loss of 3.3%).3 The largest growth was once again viral hepatitis ($32.0 billion, an 84% increase) due in large part to the combined global sales of Harvoni and Sovaldi (∼$24.5 billion in combined sales). Another area witnessing growth was multiple sclerosis ($17.4 billion, a 16.8% increase), and multiple CNS areas performed well: mental health ($34.8 billion, a 4.8% loss of 2014), nervous system disorders ($22.4 billion, a 9.9% increase), and other CNS ($19.5 billion, a 7.4% increase). Clearly, 2015 was the year for Harvoni and viral hepatitis with tremendous growth and market penetration not witnessed since the statins first launched.3,4 Still multiple CNS relevant areas show strong sales and growth. 2015 was a great year for ACS Chemical Neurosciencean IF of 4.348, a five year impact of 4.51 and assuming a leading position among peer Journals. 2015 was also a great year for global pharmaceutical sales ($954.1 billion, 9.5% growth over 2014), and Harvoni, the new hepatitis C cure, had a Published: July 20, 2016 842
DOI: 10.1021/acschemneuro.6b00177 ACS Chem. Neurosci. 2016, 7, 842−843
ACS Chemical Neuroscience
Editorial
Table 2. Top 20 Global Therapy Areas in 2015 in Terms of Sales3 rank
therapy area
sales (US $BN)
% growth
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
oncology antidiabetes pain autoimmune disorders antihypertensives respiratory agents antibacterials mental health viral hepatitis dermatologics anticoagulants lipid regulators GI products HIV antivirals nervous system disorders other cardiovascular antiulcerants other CNS multiple sclerosis vaccines
78.9 71.4 56.1 41.9 41.3 40.0 38.3 34.8 32.0 29.4 27.2 26.5 25.5 24.3 22.4 22.4 22.3 19.5 17.4 16.3
14.0 19.0 2.5 19.7 −3.3 8.0 1.0 −4.8 84.0 13.7 13.2 0.2 12.4 12.1 9.9 8.3 −3.2 7.4 16.8 14.0
tremendous year in terms of sales (and % growth). CNS therapeutics also did exceptionally well, but Abilify patent loss impacted its sales. I leave you with the same observation and question posed in 2014 “Despite the constant downsizing and lay-offs across the industry, there does appear to be an upward trend in terms of sales growthcan a global resurgence in R&D be not too far behind?”
■
Craig W. Lindsley, Editor-in-Chief AUTHOR INFORMATION
Notes
Views expressed in this editorial are those of the author and not necessarily the views of the ACS.
■
REFERENCES
(1) https://jcr.incites.thomsonreuters.com. (2) Lindsley, C. W. (2015) The 2014 Impact Factor: ACS Chemical Neuroscience Continues to Rise. ACS Chem. Neurosci. 6, 1271. (3) IMS Institute for Healthcare Informatics. See www.imshealth. com. (4) Lindsley, C. W. (2015) 2014 Global prescription medications statistics: Strong growth and CNS well represented. ACS Chem. Neurosci. 6, 505−506.
843
DOI: 10.1021/acschemneuro.6b00177 ACS Chem. Neurosci. 2016, 7, 842−843
